John Wiley & Sons

SHERPA: Green

People

  1. Breitbart
    Breitbart
  2. Nelson
    Nelson
  3. Busam
    Busam
  4. Applebaum
    Applebaum
  5. Roth
    Roth
  6. Zelenetz
    Zelenetz
  7. Ostroff
    Ostroff
  8. Rossi
    Rossi
  9. Begg
    Begg
  10. Gany
    Gany

Groups

  1. Department of Medicine (565)
  2. Population Sciences Research Program (523)
  3. Psychiatry and Behavioral Sciences, Department of (458)
  4. Psychiatry Service (328)
  5. Survivorship Research (320)
  6. Center for Hematologic Malignancies (278)
  7. GSK Faculty (256)
  8. Hematologic Malignancies, Division of (253)
  9. Sloan Kettering Institute Faculty (240)
  10. Surgery (214)
Search Within
Formats
  1. Journal Article (1361)
  2. Meeting Abstract (721)
  3. Conference Paper (110)
  4. Book Section (53)
  5. Review (46)
  6. Editorial (24)
  7. Research Letter (16)
  8. Correspondence (8)
  9. Book Whole (4)
  10. Miscellaneous (2)
  11. Guidelines (1)
Groups
  1. Department of Medicine (565)
  2. Population Sciences Research Program (523)
  3. Psychiatry and Behavioral Sciences, Department of (458)
  4. Psychiatry Service (328)
  5. Survivorship Research (320)
  6. Center for Hematologic Malignancies (278)

More Groups

People
  1. William Breitbart (88)
  2. Christian Nelson (87)
  3. Jimmie Holland (75)
  4. Klaus Busam (56)
  5. Allison Applebaum (44)
  6. Lloyd Old (41)

More People

Years
  1. 2025 (69)
  2. 2024 (72)
  3. 2023 (95)
  4. 2022 (84)
  5. 2021 (90)
  6. 2020 (104)

More Years

Publications
  1. Psycho-Oncology (632)
  2. British Journal of Haematology (273)
  3. International Journal of Cancer (268)
  4. Journal of Cellular Biochemistry (178)
  5. Annals of the New York Academy of Sciences (112)
  6. Journal of Cutaneous Pathology (91)

More Publications

Results (2346)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • CheckMate 436: Primary efficacy and safety analysis of the phase 2 study evaluating nivolumab combined with brentuximab vedotin for relapsed/refractory mediastinal gray zone lymphoma
    Meeting Abstract

    Santoro, A.; Moskowitz, A.; Ferrari, S.; Carlo-Stella, C.; Collins, G.; Fanale, M.; Francis, S.; Sacchi, M.; Savage, K.
    British Journal of Haematology (2021)

    Fulltext@MSK | Save
  • Pirtobrutinib (LOXO-305), a next generation highly selective non-covalent Bruton's tyrosine kinase inhibitor in previously treated mantle cell lymphoma and other non-Hodgkin lymphomas: Results from the phase 1/2 BRUIN study
    Meeting Abstract

    Eyre, T.; Shah, N. N.; Alencar, A.; Gerson, J. N.; Patel, M. R.; Fakhri, B.; Jurczak, W.; Tan, X.; Lewis, K.; Fenske, T.; more...
    British Journal of Haematology (2021)

    Fulltext@MSK | Save
  • Brentuximab vedotin plus chemotherapy for patients with previously untreated, Stage III or IV classical Hodgkin lymphoma: 5-year update of the phase 3 ECHELON-1 study (NCT01712490)
    Meeting Abstract

    Radford, J.; Dlugosz-Danecka, M.; Connors, J. M.; Illes, A.; Picardi, M.; Lech-Maranda, E.; Feldman, T.; Smolewski, P.; Savage, K. J.; Bartlett, N. L.; more...
    British Journal of Haematology (2021)

    Fulltext@MSK | Save
  • CPI-0610, a bromodomain and extraterminal domain protein (bet) inhibitor, in combination with ruxolitinib, in jak-inhibitor-naive myelofibrosis patients: Update of manifest phase 2 study
    Meeting Abstract

    Mead, A.; Mascarenhas, J.; Talpaz, M.; Patriarca, A.; Devos, T.; Palandri, F.; Passamonti, F.; Rampal, R.; Kremyanskaya, M.; Scandura, J.; more...
    British Journal of Haematology (2021)

    Fulltext@MSK | Save
  • CPI-0610, bromodomain and extraterminal domain protein (BET) inhibitor, as "add-on" to ruxolitinib, in advanced myelofibrosis patients with suboptimal response: Update of MANIFEST phase 2 study
    Meeting Abstract

    Somervaille, T.; Verstovsek, S.; Mascarenhas, J.; Kremyanskaya, M.; Hoffman, R.; Rampal, R.; Gupta, V.; Talpaz, M.; Granacher, N.; Leber, B.; more...
    British Journal of Haematology (2021)

    Fulltext@MSK | Save
  • ECHELON-2 (NCT01777152), a randomized, double-blind, phase 3 study of brentuximab vedotin plus cyclophosphamide doxorubicin and prednisone versus cyclophosphamide, doxorubicin, vincristine and prednisone in previously untreated patients with CD30-positive peripheral T-cell lymphoma: 5-year results
    Meeting Abstract

    Illidge, T.; Horwitz, S. M.; O'Connor, O. A.; Pro, B.; Iyer, S. P.; Advani, R.; Bartlett, N. L.; Christensen, J. H.; Morschhauser, F.; Domingo-Domenech, E.; more...
    British Journal of Haematology (2021)

    Fulltext@MSK | Save
  • CPI-0610, a bromodomain and extraterminal domain protein (BET) inhibitor, as monotherapy in advanced myelofibrosis patients refractory/intolerant to JAK inhibitor: Update from phase 2 MANIFEST study
    Meeting Abstract

    Drummond, M.; Talpaz, M.; Rampal, R.; Verstovsek, S.; Kiladjian, J. J.; Vannucchi, A.; Kremyanskaya, M.; Schiller, G.; Patriarca, A.; Van Gorkom, G.; more...
    British Journal of Haematology (2021)

    Fulltext@MSK | Save
  • Pirtobrutinib (LOXO-305), a next generation highly selective non-covalent Bruton's tyrosine kinase inhibitor in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma: Results from the Phase 1/2 BRUIN study
    Meeting Abstract

    Eyre, T.; Pagel, J. M.; Coombs, C. C.; Shah, N. N.; Lamanna, N.; Lech-Maranda, E.; Woyach, J.; Wierda, W. G.; Cheah, C. Y.; Roeker, L.; more...
    British Journal of Haematology (2021)

    Fulltext@MSK | Save
  • Long-term survivors and gilteritinib safety beyond 1 year in patients with FLT3-mutated relapsed or refractory acute myeloid leukemia: ADMIRAL trial follow-up
    Meeting Abstract

    Perl, A. E.; Martinelli, G.; Neubauer, A.; Berman, E.; Baer, M. R.; Larson, R. A.; Fathi, A. T.; Yokoyama, H.; Hosono, N.; Hasabou, N.; more...
    British Journal of Haematology (2021)

    Fulltext@MSK | Save
  • Addition of parsaclisib (INCB050465), a PI3K delta inhibitor, in patients with suboptimal response to ruxolitinib: A phase 2 study in patients with myelofibrosis
    Meeting Abstract

    Yacoub, A.; Wang, E.; Rampal, R.; Borate, U.; Kremyanskaya, M.; Ali, H.; Hobbs, G.; O'Connell, C.; Assad, A.; Erickson-Viitanen, S.; more...
    British Journal of Haematology (2021)

    Fulltext@MSK | Save